Psychedelics

By David E. Nichols. Pharmacological Reviews, 2016

1,421 citations recorded by the source corpus.

Subfields: Clinical Psychology, Molecular Biology, Organic Chemistry

View Paper: https://www.semanticscholar.org/paper/d103f7fdab5b4716b1ac3bc4a1eb30451e76f0a1

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Clinical Psychology

In Molecular Biology

In Organic Chemistry

Citations in the corpus

REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics (2019, background): “Some classic psychedelics, such as LSD, have a rich pharmacology (Nichols, 2004, 2016); however, there is compelling evidence that activation of a specific serotonin receptor subtype, the 5-HT2AR, is necessary for these compounds ’ subsequent psychedelic effects.”
Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial (2016, background): “In two recently published open-label trials, one using a single dose of ayahuasca (Osorio et al., 2015) and the other using two doses of oral psilocybin (Carhart-Harris et al., 2016), acute and enduring anti-depressant effects were reported.”
5-HT2C Receptor Structures Reveal the Structural Basis of GPCR Polypharmacology (2018, neutral): “Creating selective 5-HT2C agonists is extremely challenging, however, as off-target agonist activity at the closely related 5-HT2A and 5-HT2B receptors leads to lysergic acid diethylamide (LSD)-like hallucinations (Nichols, 2016) and cardiac valvulopathy (Roth, 2007), respectively.”
Patients’ Accounts of Increased “Connectedness” and “Acceptance” After Psilocybin for Treatment-Resistant Depression (2017, background): “Recent clinical trials have found promising safety, tolerability, and efficacy (Nichols, 2016).”
Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression (2018, background): “Like SSRIs, classic psychedelic drugs also work on the serotonin system; however, unlike the SSRIs, they are direct agonists at the 5-HT2A receptor (Nichols, 2016).”
Being for no-one (2020, background): “Like other “classic” psychedelics such as LSD and psilocybin, they are believed to alter consciousness primarily via 5-HT2A receptor agonism (Nichols, 2016).”
Psychedelics Promote Structural and Functional Neural Plasticity (2018, background): “Moreover, several psychedelics elevate glutamate levels in the cortex (Nichols, 2004, 2016) and increase gene expression in vivo of the neuro-trophin BDNF as well as immediate-early genes associated with plasticity (Martin et al., 2014; Nichols and Sanders-Bush, 2002; Vaidya et al., 1997).”
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial (2016, background): “The classic hallucinogens, which include psilocybin (psilocin) and (+)-lysergic acid diethylamide (LSD), are a structurally diverse group of compounds that are 5-HT2A receptor agonists and produce a unique profile of changes in thoughts, perceptions, and emotions (Halberstadt, 2015; Nichols, 2016).”